MeSH D011087 - polycythemia vera
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Cipla | Anagrelide | Anagrelide |  | 2005-04-18 |  |  |
| Mylan | Anagrelide | Anagrelide Mylan |  | 2018-02-15 |  |  |
| Busulfan | Busulfan |  | 2018-07-13 |  |  | |
| Novartis | Ruxolitinib | Jakavi |  | 2012-08-23 | $1,828 M | Q2/22-Q2/25 |
| Merck & Co | Interferon alfa-2b | Intron A |  | 1986-06-04 |  |  |
| Interferon alfa-2b | IntronA |  | 2000-03-09 |  |  | |
| Interferon alfa-2b | Viraferon |  | 2000-03-09 |  |  | |
| Takeda | Anagrelide | Agrylin |  | 1997-03-14 |  |  |
| Anagrelide | Xagrid |  | 2004-11-15 |  |  | |
| Barr Pharmaceuticals | Anagrelide | Anagrelide |  | 2005-04-18 |  |  |
| Hydroxyurea | Hydroxyurea |  | 1998-07-30 |  |  | |
| Rising Pharmaceuticals | Anagrelide | Anagrelide |  | 2006-06-27 |  |  |
| Apotex | Busulfan | Busulfan |  | 2019-05-07 |  |  |
| Torrent Pharmaceuticals | Anagrelide | Anagrelide |  | 2017-06-30 |  |  |
| Hospira | Busulfan | Busulfan |  | 2018-07-31 |  |  |
1
2
3
4
>
Clinical Trials
Historical Success Rate
Phase 1
70%21/30
Phase 2
15%9/62
Phase 3
74%14/19
Approved: 10Overall Success rate: 7%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use